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DIRECTORS INTRODUCTION 
 
This Annual Report sets out a summary of the activities and performance of the Bureau, 
important and relevant data in the area of driving under the influence of intoxicants and the 
Bureau’s ongoing essential role in the Road Safety Strategy 2013 – 2020.    
 
The total number of specimens analysed for alcohol in blood, urine and breath and for drugs 
in blood and urine in 2017 totalled 10,482.    This was a significant increase in the number of 
analyses compared with 2016.  Alcohol remains the most prevalent intoxicant posing a 
danger on the roads and the mean alcohol level in blood specimens analysed in 2017 was 
156mg/ml and in urine it was 181mg/100ml whilst in breath it was 45µg/100ml.    Cannabis 
and benzodiazepine classes of drugs were the next most common intoxicants found on 
analysis.  The younger male drivers continued to be the group in whom intoxicants were 
most often detected on analysis.     
 
The implementation of the Road Traffic Act 2016 was one of the major tasks undertaken and 
completed in 2017.  Preliminary drug testing devices were rolled out for use by An Garda 
Síochána at the roadside and in 86 Garda Stations nationwide.  The new concentration 
levels in blood for cannabis, cocaine and heroin resulted in a significant increase in the 
number of specimens analysed for drugs.  The confirmatory analyses for these drugs and the 
testing for drugs in oral fluid were successfully added to the Bureau’s externally recognised 
accreditation.  Training and information support in relation to preliminary drug testing and 
driving under the influence of drugs was provided for An Garda Síochána, the Prosecution 
Services,  Members of the Judiciary, Doctors and Pharmacists.     
 
In the area of preliminary breath testing the procurement and testing of new generation 
devices was  nearing completion by the end of 2017 with an expected implementation and 
roll  out in 2018.   
 
  
 
The Bureau assisted in the exceptional reviews by a number of bodies of the number of 
preliminary alcohol breath tests carried out at the roadside by the Gardaí going back to the 
beginning of the decade and provided information to: An Garda Síochána; the 
Department of Transport, Tourism and Sport; the Policing Authority; Oireachtas Members and 
Committees; and the media, to help in an understanding and assessment of this important 
road safety measure and Garda enforcement. 
 
With the increase in the number of specimens analysed and of information and data to be 
harvested from those results, this Annual Report expanded the type, breadth and depth of 
information provided in graphic format for both alcohol and drugs and this increased 
information platform will be further enhanced in 2018.   
 
The Bureau is already making preliminary preparations for the celebration of its 50th 
Anniversary in 2018 when it is anticipated there will be a special research and academic 
event to mark that important milestone. 
 
 
 
 
 
 
 
Professor Denis A. Cusack 
Director 
 
 
 
  
 
MISSION STATEMENT:  
 
 “To provide a high quality national forensic service in  
 alcohol and drug (intoxicant) detection in support of the  
effective operation of the road traffic legislation  
and contribution to road safety and medical fitness  
to drive measures.”                                                                                                
 
 
 
 
 
 
 
 
  
 
FUNCTIONS OF THE MEDICAL BUREAU OF ROAD SAFETY 
The responsibi l i ty for chemical testing of intoxicants in dr iv ing in I reland rests with the 
Medical Bureau of Road Safety which is  a corporate body establ ished in November 
1968 by the Minister for Local Government under Part V of the Road Traff ic Act, 1968.    
The Minister’s  t i t le was altered to Minister for the Environment & Local Government on 
22nd July 1997.  In June 2002 the Medical Bureau of Road Safety came under the 
aegis of the Minister for Transport under the Transfer of Departmental  Administration 
and Ministerial Functions Order 2002.   
 
Since 2011 the Medical Bureau of Road Safety is under the Department of Transport,  
Tourism and Sport.  The functions of the Bureau are laid down in the Road Traff ic Acts 
1968 –  2016. 
 
Functions of 
the Medical 
Bureau of 
Road Safety
Receipt and 
analysis for 
intoxicants of 
specimens of 
blood and urine 
forwarded to the 
Bureau
Issuing of 
Certificates of 
Analysis
Provision of 
equipment for 
the taking or 
provision of 
specimens, of 
blood and urine
Approval, 
supply,testing of 
equipment or 
apparatus for 
indicating the 
presence / 
determining the 
concentration of 
alcohol in the 
breath
Approval, supply 
and testing of 
equipment or 
apparatus for 
determining the 
presence of 
drugs in oral fluid
Research on 
drinking and 
drugs in relation 
to driving
  
 
When the Bureau was establ ished in 1968 it  commenced operating for Roadside 
Alcohol Testing, Blood and Urine Alcohol Analysis,  the I ssue of Certif icates and 
provis ion of equipment for the taking of specimens (ki ts).  
 
There have been many legis lative changes such as the introduction of evidential 
breath alcohol testing and driv ing under the influence of drugs (DUID), specimens 
provided in hospitals, specimens taken from drivers involved in col l is ions and 
mandatory alcohol testing.  Most recently the Road Traff ic Act 2016 added 
Prel iminary Drug Testing and Oral Fluid Drug Testing to include certi fying the 
concentration of a drug or drugs.  
 
The Bureau has had to expand and develop al l  aspects of i ts work whi le focusing on 
its legal responsibi l i t ies as set out in the Road Traff ic Acts (RTA) and in accordance 
with the Government’s Road Safety Strategy.  
 
Currently the Bureau has several programmes and services in operation and these 
are: 
  
 
 
Blood and Urine Alcohol 
Analysis
Breath Alcohol 
Analysis
Blood and Urine
Drug Analysis
Oral Fluid Drug
Testing
Research – Driving under 
the influence of 
Intoxicants
Professional Expert 
Witness
Corporate and  Financial Quality Assurance
  
 
The Bureau continues to keep up to date with technology and use the best methods 
of analysis.  I t has kept abreast of innovation in instrumentation in the f ield of alcohol 
and drug detection both in the laboratory and outside of the laboratory –  roadside 
and garda stations. 
 
The Bureau provides a service to the Department of Transport, Tourism and Sport, the 
Courts,  the Garda Síochána, both defence and prosecution lawyers and the public.  
 
One of the major contr ibuting factors to the operation of the Bureau is the ski l led 
members of staff employed in the Bureau. The Director i s responsible for the day to 
day running of the Bureau. The Chief Analyst is responsible for the day to day running 
of the laboratories and their  programmes.  Each programme has a programme 
manager at Pr incipal Analyst level. The Senior Administrator is responsible for the 
Corporate/Financial programme and for overal l  administration within the Bureau. The 
Bureau also has an appointed Quality Manager .   
 
(see organisational chart on page 44)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Significant Achievements & Developments during 2017 
 
Preliminary Drug Testing 
On 13th April 2017 the relevant sections of the 2016 Road Traffic Act were implemented. This saw for 
the first time in Ireland Roadside Drug Testing being carried out on drivers. The Bureau installed 86 
Preliminary Drug Testing devices in Garda Stations throughout the country and made available 50 
mobile devices. The Preliminary Drug Testing Implementation Group continued communications 
throughout the year and post implementation was renamed as the PDT Review Group. 
 
Laboratory Preliminary Drug Screening 
The Bureau continued to develop a new Preliminary Drug Screening method using LC-MS-MS for the 
analysis of drugs to replace the currently used immunoassay system. 
 
Confirmatory Drug Testing 
The Bureau implemented changes in test methods to comply with the per-se levels introduced with 
the commencement of the 2016 Road Traffic Act. All blood confirmation testing was brought in-
house from April 2017. 
 
Preliminary Breath Alcohol Testing 
The Bureau commenced a procurement for Roadside Breath Testing devices to include extra 
functionality to better suit the needs of An Garda Síochána. The initial procurement process was 
completed in December 2017 with the tender to be awarded in early 2018. 
 
Quality Assurance 
ISO 17025 accreditation was maintained in 2017 for the following tests: 
• Blood and Urine Alcohol Analysis 
• Evidential Breath Testing  
• Preliminary Breath Testing 
• Laboratory Preliminary Drug Screening  
• Cannabis confirmation in Blood and Urine 
• Benzodiazepine confirmation in Blood and Urine 
 
Under flexible scope, Drugs in Oral Fluid testing was added to the scope after full assessment by INAB. 
Extension to scope was granted following an INAB assessment to cover testing of Preliminary Drug 
Testing devices and stk testing (consumable part of the drug testing system) for use at the roadside 
and in Garda Stations in 2017. 
  
 
Health and Safety 
The Bureau continued to monitor all aspects of health and safety throughout 2017 and had no 
reportable or significant incidents in the year. 
 
Knowledge Sharing and Development 
Bureau staff and the Director presented at and attended many conferences, meetings and working 
groups related to the work of the Bureau. The Bureau hosted groups from other national and 
international agencies with the aim of sharing expertise and knowledge.  
 
The Bureau also hosted several secondary school transition year students for a week each. 
 
Bureau staff are involved in a LIMS user group along with other Public Service and Civil Service 
laboratories.  The Bureau hosted several of these meetings in 2017. 
 
Garda Seminars 
Senior Bureau staff provided various seminars to Garda groups as required throughout 2017. 
 
Director of Public Prosecutions 
Presentation given in 2017 to update the DPP on the role of the Bureau and the technology involved 
in relation to 2016 Road Traffic Act and roadside/station based drug testing of oral fluid and per se 
blood levels for drugs. 
 
 
  
 
SPECIMENS RECEIVED IN THE LABORATORY FOR ANALYSIS 
 
In 2017, a total of 3,386 blood and urine specimens were analysed for alcohol and/or drugs.  
 
There was a significant change in the number of specimens tested for drugs due to the 
introduction of the Preliminary Drug Testing (Drugs in Oral Fluid testing).  
 
 
 
Table 1 
Total Number of Specimens Received within Programmes 
 
Programme 2017 2016 Increase 
Alcohol Blood & Urine 3,386 3,019 12% 
Toxicology Blood & Urine 1,592 1,133 40% 
Evidential Breath Testing 5,512 4,988 11% 
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Blood & Urine Specimens 
 
 
  
 
ALCOHOL PROGRAMME: BLOOD & URINE 
 
In April 2017, a new Principal Analyst, Ms. Louise Lawlor was appointed as head of the Alcohol 
Programme. The Blood and Urine Alcohol Programme was merged with the Breath Alcohol 
Programme to form one Alcohol Programme.  This improved efficiency by combining staff and 
resources into the one team.  
 
The main functions of the Blood and Urine programme are: 
• The receipt and analysis of specimens of blood and urine forwarded to the Bureau  
• The determination of the concentration of alcohol in blood and urine specimens 
• The issue of Certificates of Analysis 
• The testing of spurious specimens 
• Provision of expert assistance to the Courts and the Department of Transport, Tourism and 
Sport  
• Collection and analysis of data in relation to alcohol tests 
 
 
 
 
 
 
 
 
 
  
 
 
Provision of Blood and Urine kits  
 
The number of specimen kits prepared in 2017 was 6,900 and 6,999 kits were issued (See Tables 2 & 3). 
This was an increase on the previous year in anticipation of the change in the Road Traffic Legislation 
and the possible increase in the requirement for blood provision in drug driving cases. 
 
Table 2 
Kits Prepared in Medical Bureau of Road Safety 
 
 2017 2016 
BLOOD KITS 3,700 3,100 
URINE KITS 3,200 2,700 
JUGS 2,900 2,800 
 
Table 3 
Kits issued to An Garda Síochána 
 
 2017 2016 
BLOOD KITS 3,800 3,200 
URINE KITS 3,199 2,500 
JUGS 3,300 2,600 
 
The Bureau retained a contingency supply of at least 500 of each kit type throughout the year. 
 
Blood and Urine Alcohol Analysis 
 
Blood and Urine specimens are analysed using Headspace Gas Chromatography with Flame 
Ionisation Detection (HSGC-FID). Each specimen is analysed at least twice by two different scientists 
using two different HSGC-FID systems. The results of analyses must concur before issue of a Certificate 
of Analysis.  
 
A total of 3,386 blood and urine specimens were received for analysis during 2017.  Five specimens 
were received for drug testing only as the drivers had been tested for alcohol using an Evidential 
Breath Testing instrument. In 95 (2.8%) cases, certificates were not issued either because of some 
defect in the specimen or in the documentation accompanying the specimen.  This level of “non-
  
 
issue” is a slight increase on 2016. The number of blood and urine specimens received in 2017 
increased by 12% on the number received during 2016. 
 
Number of Specimens Provided in Hospitals 
 
In 2017 there were 524 specimens provided in hospitals, this represents 15.5% of total blood and urine 
specimens.  
 
Unconscious Drivers 
 
In 2017, 6 specimens were forwarded to the Bureau for analysis following blood draws from 
unconscious drivers. 
  
Mean Alcohol Level in Blood and Urine 
 
The mean alcohol level in blood was 156mg/100ml and in urine was 181mg/100ml for 2017 excluding 
specimens which had no trace of alcohol. 
 
The max alcohol level in blood was 422mg/100ml and in urine was 438mg/100ml for 2017. 
 
Analysis of Time 
 
Specimens of blood and urine are much more likely to be provided in the evening to early hours of 
the morning as can be seen from the chart below.  
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Analysis of Day 
 
From the chart below, it is evident that more specimens of blood and urine are provided on 
Saturday, Sunday and Monday. However, the time specimens are provided can also impact these 
figures into the following morning; hence the levels indicated for Monday which could be early 
morning times. 
 
Chart 3 
 
Gender Analysis 
 
A similar pattern was seen in the male/female ratio in 2017 compared to previous years with 82% of 
drivers providing specimens being male. 
 
Table 4 
Gender Profile of Specimens received – Blood & Urine 
 
 2017 2016 
MALE 82% 80% 
FEMALE 18% 19% 
UNKNOWN 0% 1% 
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Age Profile 
 
It is notable that the age profile of drivers providing blood and urine specimens in the 25 – 34 year old 
bracket contribute to the greatest percentage of arrested drivers. However, there are significant 
numbers of drivers in the ≤24 and 35-44 age category. 
 
Chart 4 
 
 
 
Age Profile by Gender 
 
Once divided by gender there is a difference in the trend between male and female drivers.    The 
largest group for males is the 25-35yr whereas the largest group for females is the 35-44yr age group. 
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Chart 5 
 
 
Over Twice the Limit of 50mg/100ml** (Blood) or 67mg/100ml** (Urine) 
During 2017 there were 1,559 specimens certified which were two or more times over these limits. This 
figure represents 46% of the total number of specimens certified. This is a slight drop of 1.7% on 2016.  
 
** It is important to note that on receipt of specimens for testing, the Bureau does not receive driver 
classification details; i.e., Fully Licenced Drivers versus Professional, Learner and Novice Drivers where the legal 
limits are reduced. 
 
Charts 6 and 7 show the proportion of  drivers in the different bands for blood and urine respectively. 
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 Chart 6 
 
 
 
 
Chart 7 
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ALCOHOL PROGRAMME: BREATH 
 
The main functions of the Breath Alcohol programme are: 
• The approval, supply and testing of apparatus for indicating the presence of alcohol in the 
breath (roadside preliminary breath testing devices) 
• The approval, supply and testing of apparatus for determining the concentration of alcohol in 
the breath (evidential breath testing instruments) 
• Provision of expert assistance to the Courts and DTTAS. 
• Provision of training courses for EvidenzerIRL Operators and Supervisors. 
• Collection and analysis of data in relation to evidential breath alcohol tests. 
 
 
 
 
 
Roadside Breath Alcohol Testing 
 
The Bureau continued to support approximately 1,100 Draeger 6510 electronic devices issued to An 
Garda Síochána in approximately 373 Garda Stations throughout the country.  
 
A total of 1,029 devices were checked and re-issued in 2017. 
 
  
 
 
The distribution of Roadside Breath Alcohol devices is outlined in the map below. 
 
 
 
 
Invitation to Tender 
The Bureau, in conjunction with UCD Procurement, the Office of Government Procurement and 
Education Procurement in U.L, issued an invitation to tender for the supply of Roadside Breath 
Alcohol Screening Devices in 2017. These devices were to upgrade the Draeger 6510 devices due to 
limited support on the older devices and the introduction of GPS and Data download facility on the 
newer models. Some of the 6510 devices in use were over 10 years old. Four suppliers responded and 
committed to supplying a total of 3 devices for evaluation. Testing was completed in November 2017 
and the new tender awarded in early 2018. 
  
 
Evidential Breath Alcohol Testing 
The Bureau continued to support and maintain the 86 EvidenzerIRL instruments in Garda stations 
throughout Ireland.  
 
 
 
Equipment 
In 2017, a gas regulator replacement programme was undertaken for all 86 garda stations. This is due 
for completion by the end of 2018. 22 stations were completed in 2017. 
 
Training and Assessment 
The Bureau continued to provide Operator and Supervisor training courses in conjunction with An 
Garda Síochána. This is a one and a half day training course which was devised to train Garda 
Operators and Supervisors in the use of the EvidenzerIRL instrument.  The following training courses 
were held during 2017: 
• 7 Operator/Supervisor Training Courses  
  
A total of 131 Gardaí were trained as Operators including 65 who were trained as Supervisors. 
 
  
 
Testing & Visits to Garda Stations 
Bureau Scientists visited and tested each instrument that had been previously installed in Garda 
stations on at least two occasions, onsite visits totalled 202 in 2017 (also 202 in 2016).  These visits 
covered testing and maintenance and are an essential element in assuring the quality of breath 
alcohol test results for evidential purposes.  
Table 5 
2017 Certified Breath Alcohol Levels  
 
 
μg. of Alcohol per 
100ml of Breath 
 
 
2017 
 
No             (%) 
 
2016 
 
No             (%) 
 
Nil 
 
  30           1% 
 
        29         1% 
 
<= 9 
 
    320          5% 
 
249          5% 
 
10 – 22 
 
  914           17% 
 
  703        14% 
 
23 – 35 
 
  941           17% 
 
796        16% 
 
36 – 44 
 
  567           10% 
 
       534        11% 
 
45 – 66 
 
 1,326         24% 
 
    1,230        24% 
 
67 & Over 
 
1,414         26% 
 
1,447       29% 
 
Breath Alcohol Analysis 
In 2017, a total of 6,271 drivers were brought to Garda Stations with the intention of them providing 
breath specimens for alcohol analysis. 2.4% of these were cases where the EvidenzerIRL flagged a 
reason why the Section 13 certificate could not be produced, for example safeguards such as 
Mouth Alcohol or Breath Difference. Of the remaining 6,119, 10% of drivers either failed or refused to 
provide breath specimens. A total of 5,512 Section 13 Certificates were issued.  
 
Over Twice the Limit of 22 μg /100ml** (Breath) 
50% of breath specimens provided were over twice this limit.  
 
**(It is important to note that on receipt of specimens for testing, the Bureau does not receive driver 
classification details; i.e., Fully Licenced Drivers versus Professional, Learner and Novice Drivers where the legal 
limits are reduced to 9 μg.) 
 
  
 
Mean Alcohol Level in Breath 
Excluding breath specimens which returned a zero alcohol result the mean alcohol level in breath 
was 45µg/100ml in 2017.  
 
Analysis of Time  
Of the total number of valid breath specimens (5,512) 69% were provided between the hours of 9.00 
p.m. and 6.00 a.m., 14% between 4.00 p.m. and 9.00p.m. and the remaining 17% between 6.00 a.m. 
and 4.00 p.m. 
Chart 8 
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Gender in Evidential Breath Testing Specimens 
The number of male drivers required to provide a breath specimen far exceeds the number of 
female drivers, the male to female ratio being 6:1  
 
Table 6 
Gender Profile of Breath Specimens provided 
 
 2017 2016 
MALE 86% 88% 
FEMALE 14% 12% 
 
 
The age profile of drivers is shown in chart 10 and the age profile with gender breakdown is shown in 
chart 9. 
 
Chart 9 
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Chart 10 
 
 
 
The largest age category was found to be 25-34 years old at 30%. Of these 48% were between 25 
and 29 years of age.  
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TOXICOLOGY  PROGRAMME 
 
This programme is led by Principal Analyst, Dr Richard Maguire. The main functions of this programme 
in 2017 are: 
• The analysis of blood and urine specimens for the presence and/or concentration of drugs. 
• The issue of Certificates of Analysis for the presence and/or concentration of a drug or drugs.   
• Provision/maintenance of Preliminary Drug Testing Device (oral fluid) and consumables. 
• Development of new methods of drug testing.  
• Provision of expert assistance to the Courts and Department of Transport, Tourism and Sport. 
• Collection and analysis of data in relation to toxicology tests. 
• Research on drugs that cause impairment in drivers. 
 
Roadside/Station Based Drug Testing  
 
The enactment of the 2016 Road Traffic Act enabled the introduction of oral fluid drug testing at the 
roadside and in Garda stations. The Bureau managed the approval, supply and testing of the 
Draeger Drug Test 5000 oral fluid testing system for this purpose. The Bureau provided comprehensive 
training on the operation of the DT5000 to 72 members of An Garda Síochána to certified trainer 
level.  The system (pictured below) is comprised of an analyser and a cassette or STK. The STK is used 
to collect the specimen and includes the analytical component of the system. The cassette is 
inserted into the analyser once an oral fluid specimen is taken. It takes ca. 1 minute to collect a 
specimen and a further 8 minutes for the test to develop and for the analyser to report the result to 
the operator as either positive or negative. 
                        
 
 
 
  
 
 
 
The analyser is able to detect Cannabis, Cocaine, Opiate and Benzodiazepine use. 50 analysers 
were made available for mobile use and 47 were deployed and an additional 86 were provided for 
use in Garda stations. The map below indicates the locations where mobile and station base 
analysers were deployed.  
 
 
  
 
The Bureau purchased 21,000 consumable STKs for use in 2017 and 2018. The Bureau also managed 
the quality control testing of the consumable cassette (STK) part of this system and conducted 
performance testing approximately every 6 months on each analyser to ensure reliable operation. 
The MBRS were satisfied with the performance of the DT5000 in 2017 and will continue to monitor its 
performance on an ongoing basis. 
 
The number of tests on the analysers available to An Garda Síochána were collated following the first 
6 months of use, with a 12-month review planned for May 2018; however, it is important to note, this is 
not a measure of enforcement activity and the current system does not distinguish between tests 
conducted for training, demonstration, quality control or enforcement purposes. The activity from the 
introduction of the system on 13th April 2017 to October 2017 is tabulated below. 
Table 7 
 
Analyser Use Type Number of tests* 
Mobile 729 
Station Based 295 
Total 1,024 
*Review from April 13th, 2017 to October 2017 only 
 
When oral fluid is collected from a driver after testing, and is positive for a drug or drugs, the Bureau 
request that An Garda Síochána submit an “Information Form” (see below) indicating the results of 
the roadside test. This is to enable a comparison of the performance of the DT5000 and subsequent 
laboratory testing. 
  
 
 
 
In all, 191 specimens were identified as positive through receipt of this information form in 2017 and 
the correlation between the performance of the DT5000 and the lab testing was satisfactory. Of the 
191 which could be compared with lab results prevalence of drugs detected by the DT5000 was 123 
(64%) were positive for cannabis, 66 (35%) were positive for cocaine, 16 (8%) were positive for opiates 
and 10 (5%) were positive for benzodiazepines. The overwhelming detection is for illicit drugs rather 
than opiates and benzodiazepines which can be legitimately purchased and/or prescribed but can 
also be misused.  
 
 
Laboratory Testing 
 
The Bureau continued to test all blood and urine specimens under the blood equivalent alcohol limit 
of 80mg/100mls and urine equivalent alcohol limit of 107mg/100mls. In addition, specimens which 
have alcohol above the limit are tested if requested by a Superintendent or Inspector. 
 
The number specimens analysed for the presence of a drug or drugs was 1,592 in 2017. While the vast 
majority were below the limits stated above, 22 specimens were above the limits and were tested 
following a request from An Garda Siochana. Another 5 specimens were tested following evidential 
breath testing, which is an increase on specimens of this type in 2016 where there was only 1.  
 
  
 
Initial screening testing was conducted for Cannabis, Cocaine, Opiates, Methadone, 
Benzodiazepines, Amphetamines and Methamphetamines. Specimens which had been positive on 
roadside testing/station-based testing were also put through initial lab testing as previously 
mentioned.  
 
 
Of the 1,592 specimens tested 997 (63%) were found to be positive for at least one drug class on 
preliminary drug testing, while 595 (37%) were negative for the drugs targeted by the MBRS.  The  
chart below (Chart 11) shows the prevalence of the drugs detected in all specimens of blood and 
urine. As in previous years cannabis was the most prevalent followed by the benzodiazepines. The 
bar chart below (Chart 12)  shows the prevalence and extent of polydrug use in the tested 
specimens for blood and urine.  
 
Chart 11 
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Chart 12 
 
 
 
Once a positive specimen was detected at the initial screening test using ELISA immunoassay, 
confirmation was carried out using Gas Chromatography with tandem Mass Spectrometry for 
Cannabis and Liquid Chromatography with tandem Mass Spectrometry for all other drugs. In recent 
years, for practical and resource related reasons, only one drug would be confirmed even in cases 
where there were multiple positives on initial testing. All specimens received on or after 13th April 2017 
were forwarded for confirmation of all drugs detected on screening, as far as specimen volume 
permitted. Previously blood and urine specimens requiring confirmation for drugs other than 
Cannabis and Benzodiazepines were sent to LGC in the UK but this practice ceased in April 2017 as 
the Bureau developed a new blood confirmatory methodology for all drugs so that only a small 
number for urine specimens needed to be sent to LGC for confirmation. Confirmation of all drugs 
detected on screening is a very important development that will give all stakeholders the most 
complete view of drug use in drivers. This increased the workload in the area of confirmatory analysis 
significantly. The extent of this increase is highlighted in the tables below. The first table (table 8) 
shows the difference in the number of confirmation between 2016 and 2017 and this shows that the 
increase in confirmations was 75%. Table 9 shows the confirmation rate which is calculated from the 
number of specimens which had drugs confirmed following positive screening in the laboratory test.  
 
 
0%
10%
20%
30%
40%
50%
60%
1 Positive 2 Positive 3 Positive 4 Positive 5 Positive 6 Positive 7 Positive 2 or more
positives
No. of Classes Detected
  
 
 
Table 8 
DRUG CLASS 2017 2016 % Change 
Cannabis 723 546 32% 
Benzodiazepines 284 194 46% 
Cocaine 274 57 380%* 
Opiate/Methadone 201 46/7 279%* 
Amphetamine/Methamphetamine 62 16/13 113%* 
Total 1,544 879 75% 
*Prior to the 12th of April only one drug class was confirmed hence the higher percentage change for these drugs in 2017.  
 
Table 9 
 
DRUG CLASS Confirmation rate 
Cannabis 93% 
Benzodiazepines 95% 
Cocaine 94% 
Opiate/Methadone 98% 
Amphetamine/Methamphetamine 98% 
 
A review of the age and gender profiles was carried out and is detailed below showing males as 
most prevalent (Table 10) and the 16-34 year age group represent the greatest drug use in arrested 
drivers (chart 13).  
 
Table 10 
 
TOTAL CONFIRMAITON POSITIVE GENDER DATA % Male % Female 
Cannabis 93 7 
Benzodiazepines 72 28 
Cocaine 94 6 
Opiate/Methadone 72 28 
Amphetamine/Methamphetamine 97 3 
 
 
 
  
 
Chart 13 
 
 
 
Another measure introduced with the 2016 Road traffic Act was per se level for Cannabis, Cocaine 
and Heroin in whole blood (see table below). This necessitated the development and introduction of 
new analytical method for Cocaine and Heroin and amendment to the existing Cannabis method. 
 
Table 11 
 
Drug Legal Limit 
Δ9-Tetrahydrocannabinol (Cannabis) 1ng/ml 
11-nor-9-carboxy-Δ9-tetrahydrocannabinol (Cannabis) 5ng/ml 
Cocaine 10ng/ml 
Benzoylecgonine (Cocaine) 50ng/ml 
6-acteylmorphine (Heroin) 5ng/ml 
 
 
The number of drivers with blood specimens, greater than or equal to the legal limits for drugs, was 
337 and in these cases the newly introduced green concentration certificate for drug concentration 
were issued to drivers in 2017. 
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The Bureau continued to develop and improve existing methods and develop new analytical 
methods in 2017. To complement the significant developments in this area the Bureau tendered for 
and purchased two Agilent LC-MS-MS instruments in 2017. It is notable that this tender was 
conducted through the Education Procurement Service in the University of Limerick and other 
agencies benefitted from the tender process and would have the opportunity to purchase 
instruments from this exercise. 
 
LIMS (Laboratory Information Management System) developments also continued in Toxicology in 
2017 to enable electronic recording of results for new methods and newly enacted legal measures. 
 
The Toxicology section also had an article accepted for peer reviewed publication in the Journal of 
Chromatography B entitled ‘An atmospheric pressure chemical ionization liquid chromatographic-
tandem mass spectrometry method for the analysis of benzodiazepines in urine’. This is published in 
volume 1064 on the 1st of October 2017, pages 22-27.  
 
 
 
  
 
QUALITY ASSURANCE 
 
The Medical Bureau of Road Safety maintained its ISO 17025 Accreditation in 2017 for the following 
areas:  
 
 Blood and Urine alcohol analysis 
 Drug analysis 
 Breath Testing analysis   
 
An application for extension to scope to include the performance testing of the Preliminary Drug 
Testing device and STK testing was submitted to INAB (Irish National Accreditation Board) in October 
2016 for assessment in early 2017. 
 
The Bureau operates a Flexible Scope; this facilitates the addition of new drug tests or changes in 
methods to the Bureau’s Scope of Accreditation as they are developed in-house. A master list of 
flexible scope changes is maintained as part of the flexible scope procedure to record changes to 
accredited tests or add accredited tests which are in addition to the published Scope of 
Accreditation. 
 
Two tests were added to this record in early 2017: 
 
Upgrade of GC-MS instrumentation to GC-MS-MS used in the quantitation Δ9-Tetrahydrocannabinol 
and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in blood and urine and lowering the quantitation 
range of Δ9-Tetrahydrocannabinol in blood (0.5 to 35ng/ml). 
 
These tests and the extension to scope were subsequently incorporated into the Bureau’s Scope of 
Accreditation following the INAB visit in March 2017. Full details of the Scope of Accreditation are 
available at https://www.inab.ie/Directory of Accredited Bodies.  
 
 
 
 
Proficiency Testing 
 
The laboratory participates in several Proficiency Testing schemes.  
 
Table 12 details the schemes for 2017. 
 
 
 
 
 
 
 
 
 
  
 
Table 12 
 
Proficiency Testing Programmes 
Programme Provider Scheme No. Specimens 
 
Analytes 
 
Toxicology 
CAP Drugs of Abuse in 
Whole Blood and 
Urine             
8 specimens per 
annum 
Amphetamines & Stimulants 
Cannabinoids 
Cocaine & Metabolites 
Minor Tranquilisers 
Non - Opiate Narcotics 
Opiates 
 Labquality Drugs of Abuse in 
Urine 
6 specimens per 
annum 
Amphetamines & Stimulants 
Cannabinoids 
Cocaine & Metabolites 
Minor Tranquilisers 
Non - Opiate Narcotics 
Opiates 
 LGC 
Standards 
Proficiency 
Testing 
Drugs of Abuse in 
Urine 
12 specimens 
per annum 
Amphetamines & Stimulants 
Cannabinoids 
Cocaine & Metabolites 
Minor Tranquilisers 
Non - Opiate Narcotics 
Opiates, Creatinine 
 LGC 
Standards 
Proficiency 
Testing 
Toxicology 8 specimens per 
annum 
Amphetamines & Stimulants 
Cannabinoids 
Cocaine & Metabolites 
Minor Tranquilisers 
Non - Opiate Narcotics 
Opiates 
 LGC 
Standards 
Proficiency 
Testing 
Drugs in Oral Fluid 12 specimens 
per annum 
Amphetamines & Stimulants 
Cannabinoids 
Cocaine & Metabolites 
Minor Tranquilisers 
Non - Opiate Narcotics 
Opiates 
 LGC 
Standards 
Proficiency 
Testing 
Tox- Benzodiazepines 8 Specimens per 
annum 
Diazepam, Nordiazepam, 
Temazepam, Oxazepam, 
Nitrazepam 
 LGC 
Standards 
Tox – Z – Drugs 8 specimens per 
annum 
Zopiclone, Zaleplon, Zolpidem 
 
Alcohol in 
Blood and 
Urine 
Labquality Blood 8 specimens per 
annum 
Alcohol 
Labquality Urine Quantitative 4 specimens per 
annum 
pH, Creatinine & Urea 
LGC 
Standards 
Proficiency 
Testing 
Tox – Blood & Tox 
Urine 
24 specimens 
per annum 
Alcohol 
 
 
Evidential 
Breath Testing 
 
CTS, Inc. 568 Breath Alcohol 
Simulator Solution 
Analysis 
2 solutions per 
annum 
Alcohol 
 
  
 
FINANCIAL INFORMATION 
The Medical Bureau of Road Safety derives its finances from an Annual Grant from the Department 
of Transport, Tourism and Sport. The total grant allocation for the Bureau for 2017 was €5,074,000. 
CORPORATE GOVERNANCE 
The Board of the Medical Bureau of Road Safety operates in accordance with the Code of Practice 
for the Governance of State Bodies. The Board is accountable to the Department of Transport, 
Tourism and Sport and the Department of Finance. The Board meets 4 times per year and is 
responsible for the proper management of the Bureau. It makes major strategic decisions and 
reviews the Bureau’s risk management strategy and control processes on an annual basis. 
Board Members 
The Board of the Medical Bureau of Road Safety comprises of five members (including the Director) 
and is appointed by the Minister for Transport, Tourism and Sport.  
BOARD MEMBERS 
Name Position Attendance Record 
Professor Cecily Kelleher Chairman 1 of 1 
Professor Denis Cusack Board Member and Director 4 of 4 
Ms. Nicola Hayes Board Member 3 of 3 
Mr. Paul Burns Board Member 4 of 4 
Dr. Declan Bedford Board Member / Chairman 4 of 4 
Professor Patricia Fitzpatrick Board Member 1 of 1 
 
Bureau Membership and Meetings 
During 2017 the Medical Bureau of Road Safety held four meetings. These meetings were held on 30th 
March, 29th June, 28th September and 7th December 2017. 
 
 
 
  
 
Schedule of Fees and Aggregate Expenses paid to Directors during 2017 
During 2017 the following fees were paid: 
BOARD FEES PAID 
Board Member Type of Fee Paid 
Mr. Paul Burns 
 
Fee for Non-Executive members 
of Boards of State Bodies 
€5,985 
Dr. Declan Bedford 
 
Fee for Non-Executive members 
of Boards of State Bodies 
 
Fee for Chairperson of Board of 
State Body 
 
€1,496 
 
 
€6,542 
 
 
Compliance 
The Board is pleased to report that during the year ended 31st December 2017 the Medical Bureau of 
Road Safety complied with the relevant provisions of the Code of Practice for the Governance of 
State Bodies. An Internal Audit was performed. 
 
Statutory Requirements 
The Medical Bureau of Road Safety during 2017 confirms that it complied with its statutory 
requirements. 
 
Ethics in Public Office 
The members of the Board who held office at the 31st December 2017 had no interests for the 
purposes of the Ethics in Public Office Acts 1995 and 2001. 
 
Audit and Risk Committee 
The Audit and Rick Committee reviews any aspect which relates to the financial matters of the 
Medical Bureau of Road Safety. The Committee operates under formal terms of reference. The 
meetings are attended by members of the Committee and reports to the Board 4 times per year. 
External Financial Audit 
  
 
The Comptroller and Auditor General performed the annual audit of the 2016 Financial Statements 
during 2017. No significant issues were raised during the audit. 
 
Internal Audit 
The Internal Audit function is a key element in informing the Board on the effectiveness of the system 
of internal financial control. The internal auditor operates in accordance with the Code of Practice 
for the Governance of State Bodies. An Internal Audit report was prepared in relation to 2017. 
 
Procurement 
Competitive tendering is the normal policy utilized by the Medical Bureau of Road Safety in the 
procurement process. It affirms that it complied with procurement procedures and relevant EU 
Directives as set out in the Code of Practice for the Governance of State Bodies during 2017. 
 
Strategic Planning 
The Bureau compiled its Annual Strategic Plan for 2018 and its Five Year Strategic Plan 2018 – 2022 
and both strategies were forwarded to the Minister. The Plans set out the Bureau’s key objectives 
over the coming year and years in conjunction with its key actions to achieve these objectives. Both 
strategies can be viewed on the Bureau’s website. 
 
Prompt Payment of Account 
The Board acknowledges their responsibility for ensuring compliance in relation to the Prompt 
Payment of Accounts Act. Under an agreement with University College Dublin, suppliers are paid in 
the first instance by the College which is then reimbursed by the Bureau.  
 
It is the policy of the Medical Bureau of Road Safety to ensure that all invoices are paid promptly. 
University College Dublin, as a public-sector body, is required to comply with the requirements of the 
Act in relation to payments to suppliers for the supply of goods or services and therefore has strict 
procedures in place. 
 
In the case of a small number of suppliers, the Bureau will issue payment by cheque directly to the 
supplier. The controls in relation to processing of invoices, credit notes and dealing with supplier 
disputes can only provide reasonable and not absolute assurance against material non-compliance 
with the Act.  
 
 
 
 
  
 
PROFESSIONAL WITNESS 
The area of road safety traffic enforcement and in particular driving under the influence of 
intoxicants; alcohol and drugs; is one of the most litigated area in the criminal law sphere in Ireland. 
The Bureau is involved in advising on and through its scientists giving expert witness in cases before 
the Courts. 
 
In 2017 there were 8 court attendances by Bureau staff. 
  
 
STATEMENT ON INTERNAL CONTROL 
Scope of Responsibility  
On behalf of Medical Bureau of Road Safety, I acknowledge the Board’s responsibility for ensuring that an 
effective system of internal control is maintained and operated. This responsibility takes account of the 
requirements of the Code of Practice for the Governance of State Bodies (2016).  
Purpose of the System of Internal Control  
The system of internal control is designed to manage risk to a tolerable level rather than to eliminate it. The 
system can therefore only provide reasonable and not absolute assurance that assets are safeguarded, 
transactions authorised and properly recorded and that material errors or irregularities are either prevented or 
detected in a timely way.  
 
The system of internal control, which accords with guidance issued by the Department of Public Expenditure 
and Reform has been in place in Medical Bureau of Road Safety for the year ended 31 December 2017 and 
up to the date of approval of the financial statements.  
Capacity to Handle Risk  
The Medical Bureau of Road Safety has an Audit and Risk Committee (ARC) comprising of three Board 
members.   The ARC met four times in 2017.  
 
The Medical Bureau of Road Safety has also established an internal audit function which is adequately 
resourced and conducts a programme of work agreed with the ARC.  
 
The ARC has developed a risk management policy which sets out its risk appetite, the risk management 
processes in place and details the roles and responsibilities of staff in relation to risk. The policy has been issued 
to all staff who are expected to work within the Medical Bureau of Road Safety’s risk management policies, to 
alert management on emerging risks and control weaknesses and assume responsibility for risks and controls 
within their own area of work. 
Risk and Control Framework  
The Medical Bureau of Road Safety has implemented a risk management system which identifies and reports 
key risks and the management actions being taken to address and, to the extent possible, to mitigate those 
risks.  
 
A risk register is in place which identifies the key risks facing Medical Bureau of Road Safety and these have 
been identified, evaluated and graded according to their significance. The register is reviewed and updated 
by the ARC on an annual basis. The outcome of these assessments is used to plan and allocate resources to 
ensure risks are managed to an acceptable level.  
 
The risk register details the controls and actions needed to mitigate risks and responsibility for operation of 
controls assigned to specific staff. I confirm that a control environment containing the following elements is in 
place:  
 
- procedures for all key business processes have been documented,  
- financial responsibilities have been assigned at management level with corresponding accountability,  
- there is an appropriate budgeting system with an annual budget which is kept under review by senior 
management,  
  
 
-  there are systems aimed at ensuring the security of the information and communication technology 
systems,  
- there are systems in place to safeguard the assets, and  
- control procedures over grant funding to outside agencies ensure adequate control over approval of 
grants and monitoring and review of grantees to ensure grant funding has been applied for the 
purpose intended.  
Ongoing Monitoring and Review  
Formal procedures have been established for monitoring control processes and control deficiencies are 
communicated to those responsible for taking corrective action and to management and the Board, where 
relevant, in a timely way. I confirm that the following ongoing monitoring systems are in place:  
 
-  key risks and related controls have been identified and processes have been put in place to monitor 
the operation of those key controls and report any identified deficiencies,  
- reporting arrangements have been established at all levels where responsibility for financial 
management has been assigned, and  
- there are regular reviews by senior management of periodic and annual performance and financial 
reports which indicate performance against budgets/forecasts. 
Procurement  
I confirm that the Medical Bureau of Road Safety has procedures in place to ensure compliance with current 
procurement rules and guidelines and that during 2017 the Medical Bureau of Road Safety complied with 
those procedures.  
Review of Effectiveness  
I confirm that the Medical Bureau of Road Safety has procedures to monitor the effectiveness of its risk 
management and control procedures. Medical Bureau of Road Safety’s monitoring and review of the 
effectiveness of the system of internal financial control is informed by the work of the internal and external 
auditors, the Audit and Risk Committee which oversees their work, and the senior management within the 
Medical Bureau of Road Safety responsible for the development and maintenance of the internal financial 
control framework.  
 
I confirm that the Board conducted an annual review of the effectiveness of the internal controls for 2017.  
Internal Control Issues  
No weaknesses in internal control were identified in relation to 2017 that require disclosure in the financial 
statements.  
Tax Compliance 
The Medical Bureau of Road Safety is committed to compliance with taxation laws and was compliant during 
2017. 
 
On behalf of the Board of the Medical Bureau of Road Safety: 
 
Dr. Declan Bedford 
Chairman 
  
 
 
Freedom of Information 
During 2017 the Bureau received ten requests which were dealt with as follows: 
• Refused   3 
• Part Granted  2 
• Granted   3 
• Transferred to UCD  1 
• Administrative Pathway  1 
Total    10  
 
Category of Requestor: 
• Journalist   5 
• Oireachtas   2 
• Other    3 
Total    10  
GDPR (General Data Protection Regulation) 
During 2017 the Bureau carried out analysis on policies and procedures to prepare for the 
introduction of the new EU regulation on 25th May 2018. 
Staffing   
The Bureau continued during 2017 to operate within its Employment Control Framework 
complement.    
 
During the year there were changes in Bureau staffing following resignations within the scientific 
area. 
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COURSES AND CONFERENCES ATTENDED BY STAFF IN 2017 
 
1 The Operation Support Specialist, Senior Technical Officer, Technical 
Officer, two Executive Assistants and three Analysts attended Courtroom 
Skills training on 27th January 2017 in the MBRS.   
2 The Operation Support Specialist attended a two-hour eProcurement 
training course on 8th February 2017 in UCD.  
3 A Senior Analyst attended a one-day conference: UCD Women in 
Leadership, on 9th February 2017 in UCD.  
4 The IT Officer attended a five day Certified Ethical Hacker course from 
27th February to 3rd March 2017 in Sandyford, Dublin. 
5 A Senior Analyst and an Analyst attended the UK Annual Clinical 
Research and Forensic Toxicology Meeting on 2nd March 2017 in London, 
England. 
6 The Chief Analyst attended a meeting of the European Transport Safety 
Council on Preventing Drug Driving in Europe on 7th March 2017 at the 
European Parliament in Brussels.  
7 An Analyst and a Senior Analyst attended the Draeger Drug and Alcohol 
conference on the 9th and 10th of March 2016 in Manchester, England. 
8 A Senior Analyst and an Analyst attended the LTG UKIAFT joint meeting 
on the 10th March 2017 in London, England. 
9 The Operation Support Specialist, Senior Technical Officer, a Laboratory 
Assistant, two Executive Assistants and two Analysts attended a three-
hour Manual Handling Course on 23rd March 2017 in UCD.   
10 A Principal Analyst and a Senior Analyst attended the International 
Association of Chemical Testing (IACT) conference from 23rd – 28th April 
2017 in Colorado Springs, USA.  
11 An Analyst attended TrainMiC Metrology in Chemistry workshop on 25th 
April 2017 at the State Laboratory, Co. Kildare.  
12 The Director attended the two-day Faculty of Forensic and Legal 
Medicine Conference on 5th and 6th May 2017 in London, England. 
13 An Analyst attended a UKIAFT meeting on 5th May 2017 in Edinburgh, 
Scotland.  
14 Three Analysts attended the annual conference of the Irish Mass 
Spectrometry Society on 10th May 2017 in Dublin.  
15 A Principal Analyst attended Drugs in Road Traffic – Nordic Meeting 
Point, on 11th May 2017 in Stockholm, Sweden. 
16 An Analyst attended the six-day Borkenstein Alcohol Course from 14th 
May 2017 at Indiana University, USA. 
17 A Senior Analyst attended a two-day SQL Introduction course on 7th and 
8th June 2017 in Sandyford, Dublin. 
  
 
18 A Principal Analyst and a Senior Analyst attended LIMS User Group 
meeting on 5th July 2017 at FSI, Dublin. 
19 Two Senior Analysts and an Analyst attended the UKIAFT conference in 
Oxford, England on the 31st August and 1st September 2017. 
20 The Director attended a meeting of the Coroners Society of Ireland on 1st 
September 2017. 
21 The Operation Support Specialist commenced study for a Certificate in 
Safety and Health in UCD.  
22 An Analyst attended a five-day Borkenstein Drug course from 9th – 13th 
October 2017 in Austin, Texas, USA. 
23 The Director attended a meeting of the Medical Advisory Panel on 
Alcohol, Drugs and Driving, UK Department of Transport, on 10th October 
2017 at the Department of Transport, London, UK. 
 
24 The Quality Manager attended a three-day course on Lab Management 
– Role of the Quality Manager and Technical Management from 11th – 
13th October 2017 in London, England. 
 
25 An Analyst attended a 1-day Eurachem Ireland Workshop on 
Hyphenated Analytical Techniques on 19th October 2017 at Backweston 
Laboratory Campus, Co. Kildare.  
26 A Principal Analyst attended a 1-day International Symposium on Drug 
Impaired Driving in Lisbon, Portugal on 23rd October 2017. 
27 The Chief Analyst and a Principal Analyst attended a 2-day People 
Management Programme in UCD on 23rd November and 8th December 
2017. 
 
28 Throughout 2017, the Bureau organized two in-house training days to 
address specific needs of the staff. External experts were included in 
these training days and members from An Garda Síochána and the 
Director of Public Prosecutions Office delivered interesting and valuable 
seminars. MBRS staff also availed of short courses offered by UCD 
Learning and Development. Many of these courses were in the area of 
IT. 
 
 
  
 
ENERGY CONSUMPTION 
 
Under the Government’s commitment to improve public energy efficiency by 33% in 2020 
the Medical Bureau of Road Safety has registered for and is reporting through the SEAI online 
system.  The Bureau’s main energy usage is gas and electricity which is necessary for 
operating a forensic laboratory and ancillary facilities, e.g. heating and lighting, laboratory 
equipment, air handling, computers and servers.  
 
The Bureau utilizes initiatives to improve energy efficiency.  A Building Management System 
(BMS) is used to monitor and control heating, air handling units, water boiler (direct hot water 
supply) and extractor fans. Each of the four floors of the Bureau’s premises is managed 
individually and automatic controls are scheduled accordingly. Energy efficient light bulbs, 
movement sensors and timer switches have been fitted throughout the building to further 
reduced energy consumption. 
 
The Medical Bureau of Road Safety has been further liaising with UCD Building and Services 
to decrease energy consumption and discussions to implement a major lighting upgrade of 
the facility commenced in 2017. 
 
Legal Disclaimer 
 
The descriptions and statistics contained within this report are of a condensed and general 
informative nature only.  They should not, by themselves, be relied upon in determining legal 
rights or other decisions under the Road Traffic Acts.   Readers and users are advised to verify 
with their legal advisors any information on which they may wish to rely.  
  
    
      
Professor Denis A. Cusack,     Dr. Declan Bedford, 
Director.        Chairman. 
